JP2004525608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525608A5 JP2004525608A5 JP2002529131A JP2002529131A JP2004525608A5 JP 2004525608 A5 JP2004525608 A5 JP 2004525608A5 JP 2002529131 A JP2002529131 A JP 2002529131A JP 2002529131 A JP2002529131 A JP 2002529131A JP 2004525608 A5 JP2004525608 A5 JP 2004525608A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- modified
- amino acid
- human
- modified factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000001690 Factor VIII Human genes 0.000 claims 40
- 108010054218 Factor VIII Proteins 0.000 claims 40
- 229960000301 factor viii Drugs 0.000 claims 40
- 238000000034 method Methods 0.000 claims 20
- 235000001014 amino acid Nutrition 0.000 claims 19
- 150000001413 amino acids Chemical group 0.000 claims 19
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 17
- 102000057593 human F8 Human genes 0.000 claims 17
- 229960000900 human factor viii Drugs 0.000 claims 17
- 229940024606 amino acid Drugs 0.000 claims 15
- 230000035772 mutation Effects 0.000 claims 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 8
- 230000002829 reductive effect Effects 0.000 claims 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 229930182817 methionine Natural products 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 102000003839 Human Proteins Human genes 0.000 claims 3
- 108090000144 Human Proteins Proteins 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 230000005847 immunogenicity Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 229930195712 glutamate Natural products 0.000 claims 2
- 230000002947 procoagulating effect Effects 0.000 claims 2
- 230000000717 retained effect Effects 0.000 claims 2
- 230000035602 clotting Effects 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23404700P | 2000-09-19 | 2000-09-19 | |
| US23646000P | 2000-09-29 | 2000-09-29 | |
| PCT/US2001/029431 WO2002024723A1 (en) | 2000-09-19 | 2001-09-19 | Modified factor viii |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004525608A JP2004525608A (ja) | 2004-08-26 |
| JP2004525608A5 true JP2004525608A5 (enExample) | 2005-07-21 |
Family
ID=26927505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002529131A Pending JP2004525608A (ja) | 2000-09-19 | 2001-09-19 | 修飾された因子ｖｉｉｉ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6770744B2 (enExample) |
| EP (1) | EP1319016A4 (enExample) |
| JP (1) | JP2004525608A (enExample) |
| KR (1) | KR100638184B1 (enExample) |
| CN (1) | CN1205221C (enExample) |
| AU (1) | AU2001292861A1 (enExample) |
| CA (1) | CA2422902A1 (enExample) |
| HU (1) | HUP0301179A3 (enExample) |
| MX (1) | MXPA03002256A (enExample) |
| PL (1) | PL206105B1 (enExample) |
| RU (1) | RU2003107100A (enExample) |
| WO (1) | WO2002024723A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560107B2 (en) | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
| US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| MXPA04005079A (es) * | 2001-11-30 | 2004-08-19 | Univ Emory | Variantes del dominio c2 del factor viii. |
| US7485291B2 (en) | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| US7709224B2 (en) | 2003-06-03 | 2010-05-04 | Biosante Pharmaceuticals, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| US20050123997A1 (en) * | 2003-10-30 | 2005-06-09 | Lollar John S. | Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes |
| US7855274B2 (en) * | 2003-12-03 | 2010-12-21 | University Of Rochester | Recombinant factor VIII having increased specific activity |
| EP1750733B1 (en) * | 2004-05-03 | 2013-12-11 | Emory University | METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII |
| SI1824988T1 (sl) | 2004-11-12 | 2017-11-30 | Bayer Healthcare Llc | Usmerjena modifikacija FVIII |
| WO2006063031A2 (en) | 2004-12-06 | 2006-06-15 | Haplomics | Allelic variants of human factor viii |
| FR2913020B1 (fr) * | 2007-02-23 | 2012-11-23 | Biomethodes | Nouveaux facteurs viii pour le traitement des hemophiles de type a |
| CA2703948A1 (en) * | 2007-11-01 | 2009-05-07 | University Of Rochester | Recombinant factor viii having increased stability |
| CN104059155A (zh) * | 2008-05-16 | 2014-09-24 | 拜耳医药保健有限公司 | 靶向性凝固因子及其使用方法 |
| BR112012004094A2 (pt) | 2009-08-24 | 2016-03-08 | Amunix Operating Inc | composições de fator vii de coagulação e métodos para fazer e usar as mesmas |
| EP2498804A4 (en) * | 2009-11-13 | 2013-05-08 | Puget Sound Blood Ct | FACTOR VIII B CELL EPITOPARIANTS WITH REDUCED IMMUNOGENITY |
| US20110177107A1 (en) * | 2010-01-14 | 2011-07-21 | Haplomics, Inc. | Predicting and reducing alloimmunogenicity of protein therapeutics |
| US9150637B2 (en) | 2010-11-05 | 2015-10-06 | Baxalta Inc. | Variant of antihemophilic factor VIII having increased specific activity |
| HRP20221531T1 (hr) | 2012-02-15 | 2023-02-17 | Bioverativ Therapeutics Inc. | Pripravci faktora viii i postupci dobivanja i korištenja istih |
| LT2822577T (lt) | 2012-02-15 | 2019-03-25 | Bioverativ Therapeutics Inc. | Rekombinantiniai faktoriaus viii baltymai |
| US10272163B2 (en) | 2012-12-07 | 2019-04-30 | The Regents Of The University Of California | Factor VIII mutation repair and tolerance induction |
| US10093901B2 (en) | 2013-05-10 | 2018-10-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Use of specific regulatory T-cells to induce immune tolerance |
| WO2014209942A1 (en) | 2013-06-24 | 2014-12-31 | Weidong Xiao | Mutant factor viii compositions and methods |
| EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
| US10058624B2 (en) * | 2015-04-16 | 2018-08-28 | Emory University | Recombinant promoters and vectors for protein expression in liver and use thereof |
| MX2018001497A (es) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Proteinas de fusion de factor ix y metodos para producirlas y usarlas. |
| PE20231949A1 (es) | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| US20210093735A1 (en) * | 2018-04-26 | 2021-04-01 | The University Of North Carolina At Chapel Hill | Methods and compositions for treatment of hemophilia |
| RS66972B1 (sr) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc | Metode lečenja hemofilije a |
| US11795207B2 (en) | 2021-03-30 | 2023-10-24 | AAVnerGene Inc. | Modified plasma clotting factor VIII and method of use thereof |
| CN117157316A (zh) | 2021-03-30 | 2023-12-01 | 艾诺健基因治疗股份有限公司 | 修饰的血浆凝血因子viii及其使用方法 |
| CN113970279B (zh) * | 2021-10-26 | 2023-07-07 | 珠海城市职业技术学院 | 数字式螺旋测微仪 |
| CN114196677A (zh) * | 2021-12-30 | 2022-03-18 | 广西医科大学第一附属医院 | 一种高活性的凝血因子Ⅷ或Ⅷa多肽变体Gly710Ala |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663060A (en) * | 1992-04-07 | 1997-09-02 | Emory University | Hybrid human/animal factor VIII |
| US5744446A (en) | 1992-04-07 | 1998-04-28 | Emory University | Hybrid human/animal factor VIII |
| US6180371B1 (en) | 1996-06-26 | 2001-01-30 | Emory University | Modified factor VIII |
| US5888974A (en) * | 1992-04-07 | 1999-03-30 | Emory University | Hybrid human/animal factor VIII |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| CA2225189C (en) * | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| AU6770200A (en) * | 1999-08-13 | 2001-03-13 | Fred Hutchinson Cancer Research Center | Crystal of a truncated protein construct containing a coagulation factor viii c2domain in the presence or absence of a bound ligand and methods of use thereof |
| EP1460131A3 (en) * | 2000-03-22 | 2005-06-01 | Octagene GmbH | Production of recombinant blood clotting factors in human cell lines |
-
2001
- 2001-09-19 WO PCT/US2001/029431 patent/WO2002024723A1/en not_active Ceased
- 2001-09-19 PL PL366199A patent/PL206105B1/pl not_active IP Right Cessation
- 2001-09-19 AU AU2001292861A patent/AU2001292861A1/en not_active Abandoned
- 2001-09-19 HU HU0301179A patent/HUP0301179A3/hu unknown
- 2001-09-19 CA CA002422902A patent/CA2422902A1/en not_active Abandoned
- 2001-09-19 CN CNB018191495A patent/CN1205221C/zh not_active Expired - Fee Related
- 2001-09-19 JP JP2002529131A patent/JP2004525608A/ja active Pending
- 2001-09-19 KR KR1020037003993A patent/KR100638184B1/ko not_active Expired - Fee Related
- 2001-09-19 US US09/957,641 patent/US6770744B2/en not_active Expired - Fee Related
- 2001-09-19 EP EP01973263A patent/EP1319016A4/en not_active Withdrawn
- 2001-09-19 MX MXPA03002256A patent/MXPA03002256A/es active IP Right Grant
- 2001-09-19 RU RU2003107100/13A patent/RU2003107100A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004525608A5 (enExample) | ||
| RU2003107100A (ru) | Модифицированный фактор viii | |
| Maddox et al. | Connective tissue microfibrils: isolation and characterization of three large pepsin-resistant domains of fibrillin | |
| DE60035419D1 (de) | Antigene peptide aus neisseria | |
| KR880701105A (ko) | 신규 응혈촉진 단백질 | |
| WO2006056464A3 (en) | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) | |
| Yoshiyama et al. | Identification of the N-terminal residue of the heavy chain of both native and recombinant human hepatocyte growth factor | |
| AR018603A1 (es) | Un peptido, util para el tratamiento y/o profilaxis de la enfermedad de alzheimer y el sindrome de down, las composiciones farmaceuticas y vacunas que locontienen, el uso de dicho peptido para la preparacion de las composiciones farmaceuticas, una secuencia de aislado de adn, un plasmido o vector vi | |
| MXPA03001469A (es) | Proteinas sinteticas estimulantes de la eritropoyesis. | |
| JP2014510518A5 (enExample) | ||
| ZA200301610B (en) | Human coagulatiion factor VII variants. | |
| JP2003533186A5 (enExample) | ||
| JPWO1996028475A1 (ja) | Ｐｅｇ化ｈｇｆ | |
| JP2005511038A5 (enExample) | ||
| NO20011381L (no) | Preparater av streptokokk C<beta>-protein | |
| KR920009849A (ko) | 염기성 섬유아세포 성장인자 단편 및 이를 암호하는 dna 서열 | |
| WO2002008426A3 (en) | Fh-binding protein of streptococcus pneumoniae | |
| Fujii et al. | Inversion and isomerization of Asp-58 residue in human αA-crystallin from normal aged lenses and cataractous lenses | |
| RU97105374A (ru) | Модифицированные белки | |
| JP2005502332A5 (enExample) | ||
| Browning et al. | Disulfide scrambling of interleukin-2: HPLC resolution of the three possible isomers | |
| CA2270176A1 (en) | Methylated, smd homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus | |
| JP2008521795A5 (enExample) | ||
| WO2001027136A3 (fr) | Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire | |
| Ward et al. | Completion of the amino acid sequence of a Hong Kong influenza hemagglutinin heavy chain: sequence of cyanogen bromide fragment CN1 |